M Moschini1, N Fossati1, F Abdollah2, G Gandaglia1, V Cucchiara1, P Dell'Oglio1, S Luzzago1, S F Shariat3, F Dehò1, A Salonia1, F Montorsi1, A Briganti1. 1. Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. 2. Vattikuti Urology Institute and Center for Outcomes Research Analytics and Evaluation, Henry Ford Hospital, Detroit, MI, USA. 3. Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria.
Abstract
BACKGROUND: The therapeutic effect of pelvic lymph node dissection (PLND) during radical prostatectomy (RP) due to prostate cancer (PCa) is still under debate. We aimed at assessing the impact of more extensive PLND on cancer-specific mortality (CSM) in patients treated with surgery for locally advanced PCa. METHODS: We examined data of 1586 pT3-T4 PCa patients treated with RP and extended PLND between 1987 and 2012 at a tertiary referral care center. Univariable and multivariable Cox regression analyses tested the relationship between the number of nodes removed and CSM rate, after adjusting for potential confounders. Survival estimates were based on the multivariable models. RESULTS: The average number of nodes removed was 19 (median: 17; interquartile range: 11-23). Mean and median follow-up were 80 and 72 months, respectively. At multivariable analyses, Gleason score 8-10 (hazard ratio (HR): 2.5) and a higher number of positive nodes (HR: 1.06) were independently associated with higher CSM rate (all P<0.05). Conversely, higher number of removed LNs (HR: 0.94) and adjuvant radiotherapy (HR: 0.54) were independent predictors of lower CSM rates (all P⩽0.03). CONCLUSIONS: In pT3-T4 PCa patients, removal of a higher number of LNs during RP was associated with higher cancer-specific survival rates. This supports the role of more extensive PLNDs in this patient group. Further prospective studies are needed to validate our findings.
BACKGROUND: The therapeutic effect of pelvic lymph node dissection (PLND) during radical prostatectomy (RP) due to prostate cancer (PCa) is still under debate. We aimed at assessing the impact of more extensive PLND on cancer-specific mortality (CSM) in patients treated with surgery for locally advanced PCa. METHODS: We examined data of 1586 pT3-T4 PCa patients treated with RP and extended PLND between 1987 and 2012 at a tertiary referral care center. Univariable and multivariable Cox regression analyses tested the relationship between the number of nodes removed and CSM rate, after adjusting for potential confounders. Survival estimates were based on the multivariable models. RESULTS: The average number of nodes removed was 19 (median: 17; interquartile range: 11-23). Mean and median follow-up were 80 and 72 months, respectively. At multivariable analyses, Gleason score 8-10 (hazard ratio (HR): 2.5) and a higher number of positive nodes (HR: 1.06) were independently associated with higher CSM rate (all P<0.05). Conversely, higher number of removed LNs (HR: 0.94) and adjuvant radiotherapy (HR: 0.54) were independent predictors of lower CSM rates (all P⩽0.03). CONCLUSIONS: In pT3-T4 PCa patients, removal of a higher number of LNs during RP was associated with higher cancer-specific survival rates. This supports the role of more extensive PLNDs in this patient group. Further prospective studies are needed to validate our findings.
Authors: Phillip M Pierorazio; Michael A Gorin; Ashley E Ross; Zhaoyong Feng; Bruce J Trock; Edward M Schaeffer; Misop Han; Jonathan I Epstein; Alan W Partin; Patrick C Walsh; Trinity J Bivalacqua Journal: Prostate Date: 2013-09-09 Impact factor: 4.104
Authors: Peter C Albertsen; James A Hanley; George H Barrows; David F Penson; Pam D H Kowalczyk; M Melinda Sanders; Judith Fine Journal: J Natl Cancer Inst Date: 2005-09-07 Impact factor: 13.506
Authors: David S DiMarco; Horst Zincke; Thomas J Sebo; Jeffrey Slezak; Erik J Bergstralh; Michael L Blute Journal: J Urol Date: 2005-04 Impact factor: 7.450
Authors: Timothy A Masterson; Fernando J Bianco; Andrew J Vickers; Christopher J DiBlasio; Paul A Fearn; Farhang Rabbani; James A Eastham; Peter T Scardino Journal: J Urol Date: 2006-04 Impact factor: 7.450
Authors: Trinity J Bivalacqua; Phillip M Pierorazio; Michael A Gorin; Mohamad E Allaf; H Ballentine Carter; Patrick C Walsh Journal: Urology Date: 2013-09 Impact factor: 2.649
Authors: Thomas Wiegel; Dirk Bottke; Ursula Steiner; Alessandra Siegmann; Reinhard Golz; Stephan Störkel; Norman Willich; Axel Semjonow; Rainer Souchon; Michael Stöckle; Christian Rübe; Lothar Weissbach; Peter Althaus; Udo Rebmann; Tilman Kälble; Horst Jürgen Feldmann; Manfred Wirth; Axel Hinke; Wolfgang Hinkelbein; Kurt Miller Journal: J Clin Oncol Date: 2009-05-11 Impact factor: 44.544
Authors: F Abdollah; N Suardi; A Gallina; M Bianchi; M Tutolo; N Passoni; N Fossati; M Sun; P dell'Oglio; A Salonia; P I Karakiewicz; P Rigatti; F Montorsi; A Briganti Journal: Ann Oncol Date: 2013-03-18 Impact factor: 32.976
Authors: Firas Abdollah; Giorgio Gandaglia; Nazareno Suardi; Umberto Capitanio; Andrea Salonia; Alessandro Nini; Marco Moschini; Maxine Sun; Pierre I Karakiewicz; Sharhokh F Shariat; Francesco Montorsi; Alberto Briganti Journal: Eur Urol Date: 2014-06-02 Impact factor: 20.096
Authors: Heikki Seikkula; Pieter Janssen; Manuela Tutolo; Lorenzo Tosco; Antonino Battaglia; Lisa Moris; Thomas Van den Broeck; Maarten Albersen; Gert De Meerleer; Hendrik Van Poppel; Wouter Everaerts; Steven Joniau Journal: Front Oncol Date: 2017-11-22 Impact factor: 6.244